1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Sanofi-Aventis settles Allegra patent suits in US

 
• By Nancy Faigen

[C#198601345:Sanofi-Aventis]has agreed to settle some long-standing US patent infringement suits with [C#198601369:Barr Pharmaceuticals]and [C#198601169:Teva] Pharmaceutical Industriesrelated to Allegra (fexofenadine), granting the generics makers certain patent rights. As the two generics firms are already marketing US versions of the allergy drug, there will be some royalties for what has been sold in the past and royalties for future sales.

Sanofi-Aventishas agreed to settle some long-standing US patent infringement suits with Barr Pharmaceuticalsand Teva Pharmaceutical Industriesrelated to Allegra (fexofenadine), granting the generics makers certain patent rights. As the two generics firms are already marketing US versions of the allergy drug, there will be some royalties for what has been sold in the past and royalties for future sales.

The terms of the agreement pertain to generic versions of Allegra tablets 30mg, 60mg and 180mg; the agreement ends patent...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

Novartis’s ‘Pipeline-In-A-Product’ Assets Progressing Well

 
• By Kevin Grogan

CMO Shreeram Aradhye talks to Scrip about the promise shown by ianalumab, remibrutinib and a next-generation CAR-T for immunological disorders.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By Joseph Haas

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.

Sanofi CFO Says Direct Sales To Patients ‘Certainly Worth Considering’

 
• By Kevin Grogan

François Roger believes fixing inefficiencies is more important than playing with pricing.

More from Therapeutic Category

Vertex’s Pain Drug Failure Adds To Investor Doubts

 
• By Andrew McConaghie

A Phase II trial to develop a second NaV1.8 pain signal inhibitor for acute pain has failed and the US FDA has given a thumbs down on Journavx’s path to broader use in peripheral neuropathic pain.

Cardiff Pushes Towards Colorectal Cancer Phase III As Funding Questions Loom

 
• By Manas Mishra

Cardiff Oncology is open to going it alone, a partnership and even an exit as the San Diego, CA-based firm tries to push its PLK1 inhibitor through late-stage development.

Aurigene Oncology CEO On Biotech Valuations, CAR-Ts And Reimbursement Models

 
• By Anju Ghangurde

Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.